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1. Introduction 
Health spending continues to rise faster than economic growth in most OECD countries, 
maintaining a trend observed since the 1970s. Health expenditure  reached 9.5% of GDP on 
the average in 2009 [1]. But the evolution of the health spending as a share of GDP is likely 
to stabilize or fall slightly in 2011. This is principally due to lowering health spending as 
governments seek to manage budget deficits. The economic evaluation has played a 
considerable role in this process in many countries such as the United Kingdom, the USA, 
Australia and Canada. Nevertheless, little attention has been given to the evaluation of 
complementary and alternative therapies, whereas their use has increased significantly in 
recent years: In the 2007 National Health Interview Survey (NHIS), in the USA, 
approximately 38 percent of adults reported using complementary and alternative medicine 
(CAM) in the previous 12 months. In the United States, patients are spending $34 billion 
dollars (a significant amount of expenditure) on contemporary and alternative medications 
[2].Among the forms of alternative medication that have been of interest to all parties in the 
health sector is homeopathic medication. Having started in Germany over two centuries 
ago, homeopathic therapy has grown and spread over the years across Europe, America and 
the rest of the world. In most countries the government authorises, registers and supervises 
the health professionals. Regulations vary depending on the country. In some countries, 
there are no specific legal regulations concerning the use of homeopathy, while in others, 
licenses or degrees in conventional medicine from accredited universities are required [3]. 
Doctors of all specializations may without interrupting or altering chemical or any other 
therapy they prescribe to the patient, provide at the same time the homeopathic medicine of 
their choice, while the patient’s organism will be benefited especially with immediate time 
sequence between demand and offer of help. 
In many ways, homeopathic therapy is different from conventional medicine [2]. Generally, 
homeopathic therapy is based on the principle that suggests as follows: Materials that cause 
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a living organism to experience certain conditions can be used to treat those particular 
conditions for which they cause the given symptoms. This particular principle has an 
ancient origin in the research of Hippocrates [4]. For example, quinine can be used to treat 
the condition of malaria [4]. Here, it is worth mentioning that the above principle is not 
similar with the mechanism of immune response in a living organism. The differences 
concerning the traditions as well as the production and the use between homeopathic and 
conventional medicines have direct implications on the cost as we will see in the next 
paragraphs. Since homeopathy is emerging as a possible complementary or even alternative 
to contemporary medication for the treatment of various conditions, more and more 
resources will continue to be spent on homeopathic therapies and on homeopathic research. 
So, an economic evaluation of homeopathic practice is therefore useful in the direction of 
understanding the economical viability of homeopathic practice [2]. 
2. Homeopathic therapies: Τhe beliefs of costs and effectiveness for 
homeopathic therapies  
2.1. Efficacy: Does homeopathy work and how? Pre-clinical stage evidence 
It needs to be mentioned that homeopathic therapies have no molecule of an active 
ingredient per volume. Since many scientists have had a materialistic training, their 
scepticism about effectiveness is understandable.  
At pharmacology’s rational level, in 1988, the INSERM’s immunologist J. Benveniste 
claimed that IgE antibodies have an effect on certain cell type after being diluted by a factor 
of 10 120[6]. A simple experiment by scientists and professors at the renown Aerospace 
Institute of the University of Stuttgart in Germany is confirming Dr. Jacques Benveniste’s 
1988 assertion that water has an imprint of energies to which it has been exposed [7]. Also, 
electrochemical studies have shown that there is a structural difference in the chemical and 
physical nature of diluted homeopathic carriers from controls [8,9].Nevertheless, these 
results must be verified by other studies. 
Botanical science has also been helpful in evaluating the potential of homeopathy in treating 
organisms. Just like in other studies of homeopathy, modern scientists have been reluctant 
to follow up on incomplete literature that had been done by older generation scientists. 
Recently, two important observations have been made [8]. First, homeopathic substances 
were shown to slightly impact the health of healthy plants by just over 2%. Here, although 
this particular impact was observed to be low, it was statistically consistent. In unhealthy 
plants, the impact of homeopathic substances rose to 20%. Such observations have been in 
agreement with the notion that homeopathic substances (which are usually highly diluted to 
levels of zero molecules per volume) are more effective in sickly organisms than in healthy 
ones [4].  
The effectiveness of homeopathic treatment has also been applied to animals. Here, it has 
been observed that an intoxication of an animal can be reversed by the use of relevant 
homeopathic remedies [10]. A meta-analysis of 105 intoxication trials showed clear, 
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clinically relevant and significantly positive effects for homeopathic treatment [11,112] . 
Also, studies have suggested that highly diluted homeopathic treatments can replace 
missing substances in animals [13-15].  
Nevertheless, according to some authors, despite these encouraging observational studies, 
the effectiveness of the homeopathic prevention or therapy of infections in veterinary 
medicine is not sufficiently supported by randomized and controlled trials [16]. There has 
also been a number of experiments which have suggested against the effectiveness of 
homeopathic treatments. For example, some rat experiments have brought to doubt the 
effectiveness of homeopathic substances in treating diseases [10]. However, since the 
positive results have been reproduced numerous times, some scientists are suggesting a 
pointer towards the efficacy of homeopathic substances. 
2.2. No better efficacy/ effectiveness than the placebo effect in clinical trials and 
safety questions 
In some human observations, people who were taking homeopathic treatment produced 
similar results from those that were taking controls; thus, suggesting that homeopathy is 
primarily a result of the placebo effect [17-20].Over 150 clinical trials have failed to show 
that homeopathy works and the effect of the homeopathic medicine is no better than the 
placebo effect. For example, in an experiment that was done in the UAE, a meta-analysis 
study of about 3500 patients showed a positive homeopathic response in 60 patients and a 
positive placebo response in 55 patients, thus, discrediting homeopathic treatment [4].When 
all the evidence from many trials is pooled together, homeopathy is no better than a placebo. 
Νevertheless, between 1950 and 2009, 142 R.C.T there have been published studies that 
examined a total number of 74 infections . 63 R.C.T. reported a positive result 68 R.C.T. did 
not produce any convincing proof and 11 RCT reported a negative result [21]. The 
Homeopathy Faculty in London recognized 24 census takings having positive results in: 
allergy, diarrhea in children, influenza, post operational ileus, rheumatologic infections, 
seasonal allergic rhinitis , infection of the upper respiratory ducts comprising otitis media 
[19].Some researches claimed that small-scale studies have yielded positive results, but this 
is due to poor methodologies or random effects [22].  
We have to underline that according to all manuals of biostatistics medicine studies of phase 
III and afterward imply millions of persons and multiple centers in order to prove the 
“effectiveness” (and not any longer the “efficacy” of a therapy).This is not certainly the case 
for the majority of clinical trials published . In many fields much smaller unpowered 
samples predominate and studies quality according to Jadad scale is low[21,22].So, it seems 
that there is a generalized need to improve the quality of clinical studies and the problem 
does not concern only homeopathic therapies.  
In the case of innocuousness, even in large samples, there may be harmful side effects where 
there is a very scant probability of appearance. Conversely to the notion of the mean 
effectiveness, innocuousness is mostly an individual affair. So we can understand the 
danger emerging by these small trials to approve the wrong treatment in many cases. Also, 
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this specific outcome (innocuousness), is one of the main reasons of their preference  
acceptable even by the critics. The alcohol that is usually used in homeopathic drugs is 960 
that substantially evaporates and the information transmitted through water is only 4% so 
the probability to cause some reactions in patients is negligible. But even though the hazards 
from homeopathic products are modest in comparison with those of conventional 
medicines, the fast-growing popularity of homeopathy and its increasing use for self-
medication signify the need for continued vigilance to ensure the quality and safety of these 
products .  
Beyond the above arguments mentioned, there are some other problems concerning the 
degree which homeopathic therapies may be adapted to the conventional RCT’s scheme . 
Some of the reasons are that homeopathic therapies treat symptoms and not diagnosis, the 
therapies are mostly individualized. Also, instruments for the quality of life measurement do 
not comprise any items that measure the potential benefits of homeopathy as claimed by 
homeopaths including stess and control management and life attitude. Additionally, especially 
in explanatory oriented clinical studies, where the class of patients suitable for the trial is 
redefined a posteriori, patients proving unsuitable for any reason to follow allopathic 
treatment are excluded. That can produce selection bias in favor of the allopathic treatment. 
2.3. More costly than conventional medicine 
According to many opposites homeopathy is not only less effective but implies also a higher 
cost that is, conventional therapies are dominant therapies under the point of view of health 
economics. We will examine the different cost parameters to see the differences between 
homeopathic and allopathic medicines in such parameters. 
1. Consultation costs. Unlike contemporary medicine, homeopathic treatment is more 
personalized. Before prescribing medications, homeopathic consultants will need to 
review one’s emotional state, his health, among other factors in addition to disease 
symptoms. The above arrangement means that homeopathic practitioners are required 
to spend more hours with their patients when compared with contemporary health 
practitioners. A direct result of such an arrangement is high consultation costs in 
homeopathic practice. However, there is often a low follow up consultation cost. The 
initial high consultation cost is usually fruitful as most patients report better health; 
thus, a low follow up cost. Since many homeopathic practitioners will extensively 
evaluate issues that are often ignored by contemporary health practitioners, their 
patients usually report better health within a short time [25]. Another implication that is 
worth mentionning here is the necessity of specialist practitioners for patients who are 
under contemporary medications. Specialists usually charge high fees as compared to 
ordinary practitioners. Researches by Rossi et al. showed that patients under 
homeopathic medication were in less need of specialists as opposed to patients who 
were under contemporary medication [26] 
2. Medication costs. Usually, homeopathic drugs are prepared by a process that 
thoroughly mixes active ingredients with a solvent through a vigorous shaking process. 
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The process of diluting an active ingredient can be done for an infinite duration of time 
to obtain infinite quantities of medicine; thus resulting in homeopathic medications that 
have no molecule of an active ingredient per volume [2]. The economic implication of 
the above process is that homeopathic drugs can be prepared easily and at a low cost. 
Another factor that makes homeopathic drugs economical is the fact that homeopathic 
drugs are non-patented, generic, and can be easily reproduced. Consequently, costs that 
stem from copyright issues (among other costs that result from patented drugs) are 
eliminated. Also, as already mentioned homeopathy does not have the adverse events 
of conventional medicine implying additional costs. Also, a good part of homeopathic 
medicines according to homeopaths  are preventive for some epidemic infections or 
contagious and they could assist to the better resistance against the prevention.  
3. Diagnostic costs. Another factor that has helped to lower the cost of homeopathic 
medication as compared to ordinary medication is the lower requirement for laboratory 
procedures for patients that undergo homeopathic treatment as some studies indicated 
[25]. However, interpretation of these results are hampered due to the small sample size 
and the large variability between the practitioners. 
3. Homeopathy in different countries: Overal evaluations of cost 
effectiveness  
The high numbers of patients that are currently seeking homeopathic treatment in many 
countries suggest implications for health policy designers. More than a third of patients in 
the US that are suffering from allergy are seeking homeopathic treatment. [3].Among the 
countries that grant homeopathic therapies not of a lesser status we can site France, 
England, Germany, India, Bangladesh, the United States, Canada, Brazil, and many more. 
There has been a 60% growth in the homeopathic market in Europe over 10 years (1995-
2005); from €590million to €930million. 90% of homeopathic products are consumed by 
France, Germany, Netherlands, Spain, Belgium, UK and Poland [26]. Relative to population, 
France and Germany have highest consumption - 59%-[27,28] More than half of the French 
declare that have already used homeopathic medicines, a number which constantly 
multiplies. (39 % in 2004, 53 % in 2010). [29].In India, alternative treatments, including 
homeopathy, are well established and integrated into the healthcare system, with 94 per 
cent of people saying that they have faith in alternative remedies, and 62 per cent trusting 
homeopathy[28]. 15% of the population in Britain trust the homeopathy as a form of 
treatment [32].In Germany in 2006, homeopathic remedies accounted for 3.16% of sold units 
(1.08% of business volume) in the pharmaceutical sector. 0.48% of prescriptions covered by 
public health insurance were for homeopathic remedies [33]. 
On the other hand, despite the extensive use of homeopathy few are the countries that 
reimburse homeopathic medicines. Some homeopathic treatment is covered by the national 
insurance of several European countries, including France, some parts of the United 
Kingdom, Denmark, and Luxembourg. In Austria, public insurance requires scientific proof 
of effectiveness in order to reimburse medical treatments, but exceptions are made for 
homeopathy[34]. In 2004, Germany which formerly offered homeopathy under its public 
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health insurance scheme withdrew this privilege, with a few exceptions. In June 2005, the 
Swiss Government, after a 5-year trial, withdrew insurance coverage for homeopathy and 
four other complementary treatments, stating that they did not meet efficacy and cost-
effectiveness criteria. However, following the result of a referendum in 2009 the five 
therapies were reinstated for a further 6-year trial period starting from 2012[35]. 
In this section,  we will study the existing estimation of how homeopathy is more or less 
costly, less or more effective at the global level of an economy and the related consequences 
on their reimbursement. 
Nevertheless, full-scale economic evaluation of homeopathy is very difficult to take place 
because of organizational, financial and ethical reasons. Systematic reviews to conclude not 
only whether homeopathy works or harms, but also whether its adoption will lead to a 
more efficient use of resources are also very difficult to be undertaken due principally to the 
small number of existing studies by indication.  
Some observational and quasi-experimental studies recorded the outcomes and costs of 
treatment by General Practitioners (GPs) who integrated homeopathy in their practice, 
compared with those who did not: Also, national reports (governmental, federal and health 
authorities reports) conclude on the economic viability of using homeopathic therapies at a 
national level by studying the cost and/or the effectiveness of homeopathic therapies. These 
reports with the exception of the 1991 French Government Report that uses observational 
data have the form of narrative reviews .We will briefly examine these reports. 
A. National reports and statements  
A 1991 French Government Report making use of observational data revealed a significantly 
reduced cost from homeopathic care versus conventional medical care [34]. The totality of 
costs associated with homeopathic care per physicians was approximately one-half of the 
total amount of care provided by conventional primary care physicians. However, because 
homeopathy physicians, on average, saw significantly fewer patients, the overall cost per 
patient under homeopathic care was still a significant 15% less. It is also interesting to note 
that these savings appear to increase the longer a physician has been using homeopathy 
[36].  
The most complete governmental report is that of Switzerland [37]. Drawing cost data of 
participating physicians from Swiss health insurers, this review included all expenditures 
covered from consultation costs (diagnostic and therapeutic procedures), costs for 
medication (directly dispensed or prescriptions), costs for external laboratory analyses, and 
costs for physiotherapy. 
The Swiss report found that total practice costs for physicians who specialized in 
homeopathic medicine had an overall 15.4 percent reduction in overall health care costs 
associated with their practice, as compared with physicians who practiced conventional 
medicine as well as those physicians who practice other "complementary and alternative 
medicine" treatments (but not homeopathic medicine). The report comprises  a highly-
comprehensive narrative review of the wide body of preclinical and clinical and conclude 
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that effectiveness of homeopathy can be supported by clinical evidence and professional 
and adequate application regarded as safe. Reliable statements of cost-effectiveness are not 
available at the moment, but the report states that cost- effectiveness studies on individual 
complementary medical treatments clearly indicate possible savings.  
The Federal Centre of Expertise in Health Care (KCE)of Belgium has edited an analytical 
report, the second more completed national report based on narrative review[38] . This 
report concludes that the fees are higher than the other three non-conventional medical. This 
conclusion is based exclusively on cost data selected by secondary sources (patients) . 
Nevertheless, published economic evaluations are excluded from the review undertaken by 
this report .From a purely clinical perspective, by reviewing 26 systematic reviews , this 
report concludes that there is no evidence of the efficacy of homeopathy (evidence-based 
medicine) beyond the placebo effect. Nevertheless, it is not clear as to the exact exclusion 
criteria that concluded in  26 reviews having initially selected 80 studies retrieved for more 
detailed evaluation.  
A national overview of homeopathy and other CAM therapies conclude for a significant 
improvement in health outcomes and after treatment an increase in days off work [39,37].  
Beyond these reports no other reports use cost and effectiveness criteria to conclude about 
the economic viability of the homeopathic therapies. Recently, the House of Commons 
Science and Technology Committee advised that NHS funding should be stopped “since 
effectiveness of homeopathic medicines has not been proved superior than placebo 
effect”[40]. Despite this report, the Coalition stated homeopathy would continue to be 
funded, with PCTs responsible for making decisions locally.  
The specific report followed a public statement by the National Health and Medical 
Research Council (NHMRC) attesting as a basic source the English report and is of the 
opinion that there is sufficient scientific evidence to conclude that homeopathy is no more 
efficacious than placebo [41]. We are not aware of any other national report or statement at 
this time. 
Canada on the other hand (Canada Health, Ottawa) has established a research program with 
priority to the cost effectiveness evaluation for the natural products of health care such 
homeopathic medicines since it is stated that “the results of an important number of 
metaanalyses permits a cautious optimism [42].  
B. Observational and quasi- experimental studies of the overall cost and effectiveness 
A 1996 study of 130,000 prescriptions confirmed the results of the 1991 French government 
report (see above) and suggested significant benefits and savings as a result of homeopathic 
treatment. This survey also noted that the number of paid sick leave days by patients under 
the care of homeopathic physicians were 3.5 times less (598 days/year) than patients under 
the care of general practitioners (2,017 days/year). These figures suggest further benefit and 
savings to the homeopathic approach to care [43].  
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Smallwood’s report included a study by Swayne et al. published in 1992 which examined 
the prescription costs of 22 doctors in the UK found that practices which included a GP 
using homeopathy prescribed 12% fewer items of medication per patient (including both 
conventional drugs and homeopathic medicines) compared with other local practices. 
Smallwood calculates that if this figure was extrapolated to a national level the number of 
items prescribed would be reduced by 41.5 million [44,45). 
In Belgium, Wassenhoven and Yves studied 782 patients (most of who had serious 
conditions) who were undergoing homeopathic medication [25].  
The findings of Wassenhoven and Yves suggest that ordinary doctors spend as much as 
three times on drugs as compared to their homeopathic counterparts. On the other hand, 
homeopathic doctors spend only a fifth of what is spent by contemporary doctors on 
antibiotics. Such a direction indicates massive savings (about 800 million Euros) that can be 
made if all doctors in Belgium were to prescribe medicines as homeopathic practitioners [25] 
Further details for all these studies as well as for other cost studies are given in Bornhöft et al 
[37].Nevertheless, results of these studies have to be assessed with some caution because of 
some methodological limitations concerning especially their design and need of research to 
confirm the above mentioned results .  
To conclude, in relatively few countries systematic efforts have been undertaken to estimate 
the cost and effectiveness of homeopathy at a national level despite its extensive use. Health 
Technology assessments are few and do not proceed to a systematic review of cost-
effectiveness since the number of these studies by morbidity is too small. Observational and 
quasi experimental studies is well known that do not conveniently ensure the comparability 
of the groups. An attempt to understand the full economic impact of homeopathic practice 
at a macro scale level would have to consider an array of factors that are difficult to analyze 
(e.g consequences on the employment in the manufacturing sector). These are issues that are 
difficult to evaluate. The work of many researchers on the above issue can only be used to 
lay ground for a more detailed and exhaustive research. The evaluation of quality of life 
of the citizens by using adapted quality of life questionnaires and the avoidance at 
national level of adverse events by using homeopathy constitute central points for future 
research.  
4. Cost and effectiveness of homeopathy by indication: A critical review 
of economic evaluation studies 
Methods 
For the assessment of the trial based economic evaluations we have used the International 
Society of Pharmacoeconomics and Outcomes Research (ISPOR) RCT CEA Task Force 
Report. For the other types of studies as well as for the global assessment and their 
comparison with studies of conventional medicine, we have used BMJ guidelines [47]. We 
have compared also these results with results from systematic reviews in conventional 
medicine [48,49]. 
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More analytically, the results of a review [49] of conventional medicine have been used as 
well as the reviews for some studies of the Centre for Reviews and Dissemination of the 
University of York [51] that have been completed by the author in order to compare the 
criteria completion between homeopathic and conventional medicine in the case of Trial 
Based Economic Evaluations. As there are not yet specific guidelines for economic 
evaluations based on observational studies, items from the BMJ Checklist have been 
additionally used to make possible the assessment of all studies. The results of a review [49] 
of conventional medicine studies have been used and completed in order to compare 
statistically the criteria completion between homeopathic [53,66-70] and conventional 
medicine studies [71-79]. We have completed this review by Centre for Review and 
Dissemination Reviews for some studies [50] as well as by author review. 
We have selected only full economic evaluations for our review focusing on special 
indications. Full economic evaluations compare at least 2 different strategies  and measure 
both costs and  health results (cost effectiveness/cost consequences, cost utility and cost 
benefit).Cost-benefit analysis attempt to value the consequences of programs in money 
terms [50]. The cost effectiveness analysis in its classical form, considers a single measure of 
output and the results are presented in the form of a cost effectiveness ratio. An other 
version of the cost effectiveness analysis, the cost consequences analysis presents an array of 
output measures alongside costs without aggregation. In the cost utility analysis the 
consequences are adjusted by health state preference scores [50]. 
Research strategy 
We researched the following electronic databases from January 1999 to January 2012: DARE, 
NHS EED and HTA Medline, EMBASE, AMED, Alt-Health-Watch, and the Complementary 
and Alternative Medicine Citation Index via NCCAM and the National Library of Medicine 
(NLM). Researching has been restricted to English, French and  Greek language journals and 
human studies with the keywords: homeopathy, and costs or cost analysis or cost-benefit, or 
cost-effective or cost utility economic analysis, or economic evaluation.  
Data analysis 
Because of too small sample size of studies selected, in the case of Trial Based Economic 
Evaluations no statistical test has been used to detect any differences between homeopathic 
and conventional medicine studies on the completion of the above mentioned criteria. For 
the assessment of all economic evaluations based on BMJ Checklist, Fisher’s exact mid-p test has 
been used to test the homogeneity between the 2 groups for each quality criteria as well as 
for the total of the quality criteria. Fisher’s exact mid-p test is the mid-p version of Fisher’s 
exact conditional test, only half the probability of the observed outcome is included in the 
mid-p-value [80]. The resulting test is less conservative than Fisher’s exact test, and its 
performance approximates that of an unconditional test. For the statistical analysis R 
software has been used [81]. 
Results 
We have detected 186 records as well as 3 additional records identified by other sources 
(University of Lyon I). 80 duplicates have been detected and deleted. 25 full text articles have 
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been detected and selected   for eligibility (Figure 1) [82]. Eight of these publications   met   the 
criteria of full economic evaluations, whereas the others were partial economic evaluations 
and/ or did not focus on special indications. One of these publications comprises a randomized 
trial, an observational study and a review that we will study separately. So we will study 10 
studies in the total comparing homeopathy with conventional medicine. Three of these studies 
were randomized clinical trials, 3 observational studies   and one study was a review.  
Trials based economic evaluations review 
Details of the 3 studies [52-54] comparing homeopathy with conventional medicine [55-62] 
are given below (Table 1). 
 
Authors , 
country and 
year of 
publication 
Indication Type of 
economic 
evaluation 
Patients groups Health Effects 
of 
Homeopathy 
compared to 
Conventional 
medicine 
Cost of 
Homeopathy 
compared to 
Conventional 
medicine 
Paterson et al, 
(2003),United 
Kingdom[52]  
Dyspepsia Cost 
effectiveness
a. acupuncture 
b. Homeopathy 
c. normal GP 
care 
No significant 
differences 
(a=5%) 
No significant 
differences 
(a=5%) 
Kneis and 
Gandjour,2009, 
Germany[53] 
Acute 
Maxillary 
Sinusitis 
Cost utility  
 
a. Homeopathy 
b. Placebo (no 
active treatment)
 
Significant 
differences in 
favor of 
homeopathy 
(a=5%) 
Significant 
differences in 
favor of 
homeopathy 
(a=5%) 
Thompson et 
al, 2011,United 
Kingdom[54] 
Asthma Cost 
effectiveness
a. Homeopathic 
treatment 
b. Usual care 
No significant 
differences 
(a=5%) 
No significant 
differences 
(a=5%) 
Table 1. Trial Based Economic Evaluations comparing homeopathy with conventional medicine 
Table 2 presents the results of the review. As can be seen, no important deviation has been 
observed between homeopathic and conventional medicine studies. All studies comparing 
homeopathy with conventional therapy (100%) are pragmatically oriented to measure the 
effectiveness versus efficacy with some stricter criteria for inclusion in the third study 
reasonable for this type of intervention (criterion1). Also, 5 out of 8 (63%) of conventional 
studies seem to follow a more pragmatic design oriented to measure effectiveness rather 
than efficacy despite the stricter inclusion criteria of 4 out of 8 studies of conventional 
medicine. Three of these studies are considered as more explanatory [63] since they do not 
use Intention to Treat Approach although this approach in recent years has almost 
universally dominated [64].  
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ISPOR’s criteria[46] 
Review of 
homeopathic 
medicines studies 
N (%) 
Reviews of 
conventional 
studies  
N (%) 
A. Clinical trial design   
1.Trial design should reflect effectiveness rather than 
efficacy when possible 
3(100) 8(63) 
2. Full follow-up of all patients is encouraged. 3(100) 8(75)* 
3. Describe power and ability to test hypotheses, given 
the trial sample size. 
3(0) 8(25) 
4. Clinical end points used in economic evaluations 
should be disaggregated 
3(100) 8(100) 
5. Direct measures of outcome are preferred to use of 
intermediate end points. 
3(100) 8(100) 
B. Data elements   
6. Obtain information to derive health state utilities 
directly from the study population 
2(50) 8(80) 
7. Collect all resources that may substantially influence 
overall costs; these include those related and unrelated 
to the intervention 
2(33) 8(38) 
C. Database design and management   
8. Collection and management of the economic data 
should be fully integrated into the clinical data. 
3(100) 8(63) 
9. Consent forms should include wording permitting the 
collection of economic data, particularly when it will be 
gathered from third-party databases and may include 
pre- and/or post-trial records 
3(0) 8(0) 
D. Analysis   
10. The analysis of economic measures should be guided 
by a data analysis plan and hypotheses that are drafted 
prior to the onset of the study 
3(0) 8(0) 
11.1 Intention-to-treat analysis 3(100) 8(63)* 
11.2 Common time horizon(s) for accumulating costs 
and outcomes 
3(100) 8(75) 
11.3 Within-trial assessment of costs and outcomes 3(100) 8(100) 
11.4 Assessment of uncertainty is necessary for each 
measure 
3(0) 8(13) 
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ISPOR’s criteria[46] 
Review of 
homeopathic 
medicines studies 
N (%) 
Reviews of 
conventional 
studies  
N (%) 
11.5 Common discount rate applied to future costs 
and outcomes 
NA** NA 
11.6 An accounting for missing and/or censored data 3(75) 8(100) 
12. Incremental costs and outcomes should be measured 
as differences in arithmetic means, with statistical 
testing accounting for issues specific to these data 
3(33) 8(13) 
13. One or more summary measures should be used to 
characterize the relative value of the intervention 
3(33) 8(63) 
14.1 Sampling uncertainty accounting  1(100) 8(63)* 
14.2 Parameter uncertainty accounting 3(33) 8(38) 
14.3 Protocol-driven resource use are addressed (in the 
design phase) 
3(3) 8(13) 
14.3 Unrepresentative recruiting centers are addressed 3(100) 8(100) 
14.4 Inclusion of study sites from countries with varying 
access and availability of health-care services is addressed
3(0) 8(0) 
14.5 Restrictive inclusion and exclusion criteria are 
addressed 
3(100) 8(63) 
14.6 Artificially enhanced compliance is addressed 3(100) 8(75) 
15. Multinational trials require special consideration to 
address inter-country differences in population 
characteristics and treatment patterns 
NA** 1(0) 
16. When models are used to estimate costs and 
outcomes beyond the time horizon of the trial, good 
modeling practices should be followed.. 
NA NA 
17. Models should reflect the expected duration of the 
intervention on costs and outcomes. 
NA NA 
18. Subgroup analyses (ex post) are encouraged NA NA 
E. Reporting the results   
19. Patient demographics are reported 3(100) 8(63) 
20. Trial setting is reported 3(100) 8(100) 
21. Inclusion and 
exclusion criteria are reported 
3(100) 8(100) 
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ISPOR’s criteria[46] 
Review of 
homeopathic 
medicines studies 
N (%) 
Reviews of 
conventional 
studies  
N (%) 
22. Protocol-driven procedures 
that influence external validity are reported 
3(0) 8(13) 
23. Intervention 
and control arms are reported 
3(100) 8(100) 
24. Time horizon for the
intervention and follow-up are reported.
3(100) 8(100) 
25. Key clinical findings are reported 3(100) 8(100) 
26. Reporting should distinguish economic data 
collected as part of the trial vs. data not collected as part 
of the trial 
3(100) 8(100) 
27. Amount of missing and censored data
 
3(67) 8(63)* 
28. If imputation methods are used, the method should 
be described. 
1(100) 2(100)* 
29. Methods used to construct and compare costs and 
outcomes, and to project costs and outcomes beyond the 
trial period should be described.
3(100) 8(75) 
30. The results section should include summaries of 
resource use, costs, and outcome measures, including 
point estimates and measures of 
uncertainty 
3(0) 8(0) 
31. Results should be reported for the time horizon of 
the trial (and for projections)
3(100) 8(100) 
32. Graphical displays are recommended for results not 
easily reported in tabular form 
1(100) 6(33) 
* Comparable estimates available from Polsky et al, 2006 
** Not appropriate 
Table 2. ISPOR’s Good Research Practices  
Power calculations, (criterion 3), were not performed in the planning phase of the study in 
none of the studies.(0%) treating homeopathy (however, power calculations were performed 
retrospectively in the first study [52].  
One out of the three studies (33%) of homeopathy and 3 out of 8 (38%) of the studies of 
conventional medicine have measured some additional costs (criterion 7) beyond direct 
health costs. 
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None of the homeopathy (0/3) and conventional medicine studies (0/8) include in the 
consent form wording permitting for economic data collection (although in the study of 
Thompson et al [54] cost data are collected by children’s parents.  
None of the homeopathy (0%) or conventional medicine studies (0%) establish the 
hypotheses with a data analysis plan (criterion 10). No discount rate has been applied, 
(criterion 11.5), as the study period for each participant was 1 year in all studies. 
Whereas all homeopathic medicine studies use p- values for hypotheses tests (100%), and 
respectively 6 out of 8 conventional medicine studies (75%), only one conventional medicine 
study reports confidence intervals for point estimates of all measures (criterion 11.4) and 
none homeopathic study. 
Sensitivity analysis (criterion 14.2) has been used by the one of the three homeopathic 
studies (33%) whereas 3/8 conventional studies (38%) use sensitivity analysis for costs and 
outcomes. All homeopathic studies (100%) and 7 out of 8 of conventional studies (88%),, 
have been well addressed by the design the protocol induced procedures except one study 
of conventional medicine (criterion 14.3) . Nevertheless, in the report of results (criterion 23), 
there is no mention made in homeopathic studies (0%) concerning them as to whether there 
were observed and addressed or not except for one study of conventional medicine (13%) to 
which they have been spotted and measured). 
Finally, the 2 categories of studies present proportional weakness and strengths with the 
biggest differences in favor of conventional medicine focused on aggregated outcomes (2/3 
trials of homeopathy use cost consequences analyses). The trial based economic evaluations 
comparing homeopathy with conventional medicine do not seem to be of lower quality than 
studies of conventional medicine and complete the majority of the ISPOR’s criteria. Also, 
homeopathy clinical trials are for some aspects more adapted to the traditional clinical trials 
guidelines offering better information on patient characteristics and flow [65].Additionally 
they avoid some aspects of explanatory design a more pragmatic design such as stricter 
eligibility criteria and no intention to treat approach. Nevertheless, no definitive conclusions 
can be extracted because of the too small sample sizes. 
4.1. BMJ checklist including all full economic evaluations 
Information for homeopathic studies included in this review is given on Table 3.The quality 
of homeopathic economic evaluation studies seems to constantly progress given that more 
recent studies are characterized by an improved design and more detailed reports, as is the 
case with conventional studies [4]. As can be seen,(Table 4), a significantly superior number 
of homeopathic studies defines clearly the aspect of the economic evaluation (criterion 3). 
Also, details of the subjects from which values were obtained are given more frequently by 
homeopathic studies (criterion 13). On the other hand, conventional studies use more 
frequently sensitivity analyses (criterion 27) as well as incremental analyses and aggregate 
clinical outcomes (criteria 31 and 32), as the majority of homeopathic studies included use 
cost consequences analyses (80%).Finally, both categories of studies present deficiencies 
 
Evaluating Homeopathic Therapies for Contemporary Health Care: An Evident Priority 47 
concerning the justification of the form of economic evaluation chosen. The overall 
percentage of studies that complete BMJ criteria is 70.6 % for homeopathic studies and 
78.6% for conventional studies. By the mid-p version of Fisher’s exact conditional test we 
conclude that the differences observed between the 2 groups of studies aren’t statistically 
significant. (mid p-value=0.20). Consequently, we accept the homogeneity between 
homeopathic and conventional medicine studies on the BMJ guidelines completion.  
 
Authors year 
of publication 
and country 
Morbidity 
studied 
Type of 
economic 
evaluation 
Patients 
groups 
Cost of 
Homeopathy 
versus 
conventional 
medicine 
 
Health Effects 
of 
Homeopathy 
versus 
conventional 
medicine 
Stagnara et al, 
(2004), 
France [66] 
Bronchiolitis 
(neonatal) 
Cost 
effectiveness 
a. Homeopathy 
b. usual care 
 
Significant 
differences 
(a=5%) 
Less costly 
significant 
differences 
(a=5%) 
More effective 
Veinchtock et 
al, (2000) 
France [67] 
Anxiety 
disorders 
Cost 
consequences  
a. Homeopathy
b. Usual care 
No significant 
differences 
(a=5%) 
No significant 
differences 
(a=5%) 
Trichard et al, 
2005, 
France [68] 
Acute 
Rhino-
pharyngitis 
(Children) 
Cost 
effectiveness 
 
a. Homeopathy
b. Usual care 
Significant 
differences 
(a=5%) 
Less costly 
Significant 
differences 
(a=5%) 
More effective 
Witt et al, 2005, 
Germany [69] 
Headache  
Low back pain 
Depression  
Insomnia 
Cost 
effectiveness 
a. Homeopathy 
b. usual care 
 
No significant 
differences 
(a=5%) 
Significant 
differences 
(a=5%) 
More effective 
Witt et al, 2009, 
Germany [70] 
atopic eczema 
(children) 
Cost 
effectiveness 
a. Homeopathy
b. Usual care 
Significant 
differences 
(a=5%) 
More costly
No significant 
differences 
(a=5%) 
Kneis and 
Gandjour, 
2009, 
Germany [53] 
Acute 
Maxillary 
Sinusitis 
Cost utility a. Homeopathy
b. Placebo  
Significant 
differences 
(a=5%) 
Less costly
Significant 
differences 
(a=5%) 
More effective 
Kneis and 
Gandjour, 2009 
[53] 
Acute 
Maxillary 
Sinusitis 
Cost 
effectiveness 
a. Homeopathy 
b. 
Antibacterials 
Less costly  Significant 
differences in 
favor of 
homeopathy 
 
Table 3. Non randomized studies for homeopathic treatment 
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Items from the BMJ Checklist [47] 
Review of 
homeopathic 
medicines 
studies N(%) 
Reviews of 
conventional 
studies 
N(%) 
Mid p-
value 
Study design 
1.The research question is stated 10(100) 9(100) 0.5 
2. The economic importance of the research 
question is stated 
10(80) 9(78) 0.5 
3. The perspective of the analysis is stated 10(100) 9(67)* 0.04 
4. The rationale for choosing the 
alternatives is stated 
10(90) 9(100) 0.5 
5. The alternatives being compared are 
clearly described 
10(90) 9(100) 0.5 
6. The form of economic evaluation used is 
stated 
10(50) 9(89) 0.07 
7. The choice of form of economic 
evaluation is justified
10(0) 9(11) 0.09 
Data collection 
8. The source(s) of effectiveness estimates 
are stated 
10(100) 9(100) 0.5 
9. Details of the effectiveness study are 
given  
10(100) 9(100) 0.5 
10. Primary outcome measures are clearly 
stated  
10(90) 9(89) 0.5 
11. Methods to value health states are 
stated  
6(100) 9(89)* 0.5 
12. Details of the method of synthesis or 
meta-analysis of estimates are given 
1(100) 5(20) - 
13. Details of the subjects from which 
values were obtained are given  
6(100) 9(56) 0.05 
14. Productivity changes are reported 
separately  
10(60) 9(44) 0.33 
15. The relevance of productivity changes is 
discussed  
10(20) 9(33) 0.31 
16. Quantities of resources are reported 
separately from unit costs  
10(70) 9(78) 0.5 
17. Methods for the estimation of quantities 
and unit costs are described  
10(100) 9(100| 0.5 
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Items from the BMJ Checklist [47] 
Review of 
homeopathic 
medicines 
studies N(%) 
Reviews of 
conventional 
studies 
N(%) 
Mid p-
value 
18. The currency and price date should be 
recorded 
10(90) 9(89) 0.5 
19. Details of any adjustment for inflation, 
or currency conversion are given 
NA 3(75) - 
20. Details of any model used are given  NA** 6(100) - 
21. The choice of the model and its key 
parameters are justified 
NA 6(33) - 
Analysis and interpretation of results 
22. Time horizon of costs and benefits is 
stated  
10(100) 9(100) 0.5 
23. The discount rate is stated  NA 6 (86) - 
24. The choice of discount rate is justified  NA 6(33) - 
25. An explanation is given if costs and 
benefits not discounted  
10(30) 3(0) 0.5 
26. Details of statistical tests and confidence 
intervals are given for stochastic data  
9(56) 3(67) 0.5 
27. The approach to sensitivity analysis is 
given  
10(40) 9(89)* 0.03 
28. The choice of variables for sensitivity 
analysis is justified 
10(40) 9(67) 0.21 
29. The ranges over which variables are 
varied are stated 
10(40) 9(78) 0.08 
30. Relevant alternatives are compared 10(100) 9(100) 0.5 
31. Incremental analysis is reported 10(20) 9(89) 0.003 
32. Major outcomes are presented 
disaggregated and aggregated 
10(20) 9(89) 0.003 
33. The answer to the study question is 
given 
10(100) 9(100) 0.5 
34. Conclusions follow from the data 
reported 
10(100) 9(100) 0.5 
35. Conclusions are accompanied by the 
appropriate caveats 
10(80) 9(100) 0.23 
* Comparable estimates available from Pirraglia et al, 2004 
**Not Appropriate 
Table 4. BMJ Checklist  
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5. Discussion 
To conclude, few are the economic evaluation studies, but not of apparent or significantly 
lower quality than that of conventional medicine. And that despite the fact that the majority 
of the studies of the conventional medicines selected are published in journals with high 
impact factor [71-79]. The majority of homeopathic studies are observational whereas 
randomization is generally accepted as the most objective manner to have comparable 
groups. It is known that we should not generally use observational data to establish or 
attribute a difference between therapies, but they can be used to estimate the economic 
consequences of such a difference [83] 
Nevertheless, some observational studies under evaluation particularly addressed this 
problem and prove that their groups are comparable in basic medico-demographic 
characteristics [66,67]. Also, many of the conventional studies comprised in the BMJ criteria 
evaluation use modeling approaches and one of them is based exclusively on expert opinion 
[78] that is classified in the lowest degree in the hierarchy of evidence. This probably is one 
of the reasons why the majority of these studies use sensitivity analysis in contradiction to 
homeopathic studies as is the dominating method of handling uncertainty in modeling 
studies (being nevertheless complementary and not substitute of the handle of uncertainty 
in stochastic approaches).  
The limitations of these reviews are similar to those of other reviews. First, the only one 
reader was not blinded to journals and article authors, possibly having influenced results. 
To maximize accuracy, data extraction was performed many times -at least twice for each 
paper. Second, the measures of study quality depend on the information reported in an 
article, and no attempt was made to judge the merits of clinical or modeling assumptions 
and model choice made in the analyses. Also, no quality criteria exist for the amount of 
missing data that in some studies of conventional medicine not only surpass 15% of the data 
[85] in some RCT but reach even 79% in a specific study [59].Third, the number of reviewed 
studies was small. Nevertheless, to diminish the coservatiness of the statistical tests for type 
I error we have used Fisher’s conditional mid-p test. Finally, while the strategy for 
identification, review, was rigorous, it is possible that some studies meeting finally the 
criteria of this review were not included [86]. 
6. Conclusions 
Homeopathy is used almost worldwide by an important number of patients. Among the 
countries that grant homeopathic therapies not of a lesser status we can site France, 
England, Germany, India, Baglandesh, the United States, Canada, Brazil, and many more . 
France, England, Germany also are the countries that seem to dominate in the research on 
the efficiency of homeopathy. Some governmental reports support the financing of 
homeopathy based on reviews or on quasi experimental studies, some others are extremely 
negative. The financing or not of the homeopathic therapies by a third payer has clear 
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consequences on the budgets of thousand of citizens who use homeopathy and on the 
accessibility of these therapies by the more vulnerable social categories. Because of their 
popularity, governments should be busy with homeopathy more seriously as well as with 
the framework of homeopathy and what it entails, that is:  
Firstly, Good Manufacturing Practices such as cleanrooms must be applied on homeopathic 
products in order to ensure their quality. 
Also, the need of assessing these therapies so as to find out which is the exact extension that 
truly is beneficial to the state and society making their funding necessary.  
The debate with regard to efficacy/effectiveness and efficiency of homeopathy has 
dominated the scene the last decades. On the other hand, the quality of homeopathic 
economic evaluation studies seems to constantly progress given that more recent studies are 
characterized by an improved design and more detailed reports, as is the case with 
conventional studies. The trial based economic evaluations comparing homeopathy with 
conventional medicine do not seem to be of lower quality than studies of conventional 
medicine and complete the majority of the ISPOR criteria. Also, there are not statistically 
significant differences between studies of conventional and homeopathic medicine based on 
BMJ quality criteria. Certainly, the need for further improvement of both 2 categories of 
studies is obvious .And the greatest problem with homeopathic studies is their limited 
number.Νevertheless, despite objections there emerge serious indications of effectiveness 
and efficiency concerning homeopathic therapies. Yet the health effect ought to be proven 
through further well designed randomized trials. 
Crossover design that allows robust estimates of intraindividual consistency of response 
using placeo-control groups and allows for preference assessments of benefit/tolerability 
ratios seem to be appropriate in case of moderate chronic diseases (e.g. allergy, 
rhumatology).Also, extended cross over designs or Ν of 1 trials seem to be more appropriate 
in diseases where treatments even of conventional medicine are highly individualized (e.g 
autism). 
The trade off between conventional and homeopathic medicine concerning participant 
eligibility criteria is another crucial point of organized trials with homeopathic medicines. 
The development of multiple large and more pragmatically oriented clinical trials would 
make it possible to make viable effectiveness comparisons between specific patient groups. 
Additionally, it will permit to compare the resulting benefit to the avoidance of side effects 
in the case of homeopathic medicines.  
Also, the enrichment of the quality of life questionnaires comprising such items in order to 
measure the potential benefits of homeopathy as claimed by homeopaths, including stess 
and control management and life attitude will be very useful in that they helped surface the 
effects of homeopathic treatments in the well being of citizens. Only by taking into 
consideration all the specific parameters we may a arrive at strong conclusions for the 
efficiency of homeopathy.  
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On a next stage the dimarginalization of homeopathy practitioners and the use of 
homeopathic treatments by all doctors in the fields where their efficiency would have been 
proven, would lead to optimization of medical practices for the benefit of society. 
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